Head-to-head evidence
Milsaperidone (VHX-896) vs Paliperidone palmitate (Erzofri)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Milsaperidone (VHX-896)
Marketed by Vanda Pharmaceuticals
NCT06494397 · Phase 1 · completed
Every participant in this trial received both VHX-896 and iloperidone, just in a different order, so there is no separate group that shows what happens without VHX-896, and nobody was blinded to which drug was being given at each stage. The trial measured drug levels in the blood to compare the two products, not any change in psychiatric symptoms, and results have not been posted yet.
Paliperidone palmitate (Erzofri)
Marketed by Luye Pharma Group
NCT03751488 · Phase 1 · completed
In this trial, paliperidone palmitate (INVEGA SUSTENNA) served as the reference comparator against which an investigational competitor formulation, LY03010, was measured for pharmacokinetics; the study was open-label with no blinding, and no results have been posted.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Milsaperidone (VHX-896)'s landscape · Paliperidone palmitate (Erzofri)'s landscape